Overview of models and tools for the prediction of POD24
| Model/tool . | Type . | Time point . | PPV (%) . | NPV (%) . | Sensitivity (%) . | Specificity (%) . | Reference . |
|---|---|---|---|---|---|---|---|
| FLIPI | Clinical | Baseline | NA | NA | 64 | 67 | 3 |
| 33 | 87 | 70 | 58 | 4 ∗ | |||
| FLIPI2 | Clinical | Baseline | NA | NA | 41 | 60 | 3 |
| PRIMA-PI | Clinical | Baseline | 28 | 87 | 52 | 70 | 5 † |
| NA | NA | 35 | 68 | 3 | |||
| m7-FLIPI | Clinical + genetic | Baseline | 48 | 84 | 43 | 86 | 4 ∗ |
| NA | NA | 32 | 79 | 3 | |||
| POD24-PI | Clinical + genetic | Baseline | 40 | 87 | 61 | 73 | 4 ∗ |
| PET/CT TMTV‡ | Imaging | Baseline | 22 | 90 | NA | NA | 6 |
| PET/CT Deauville | Imaging | EOI | 45 | 93 | 56§ | 90§ | 1 |
| ctDNA | Molecular | EOI | 50 | 92 | 40§ | 94§ | 1 |
| PET/CT + ctDNA | Imaging + molecular | EOI | 86 | 94 | 46§ | 99§ | 1 |
| Model/tool . | Type . | Time point . | PPV (%) . | NPV (%) . | Sensitivity (%) . | Specificity (%) . | Reference . |
|---|---|---|---|---|---|---|---|
| FLIPI | Clinical | Baseline | NA | NA | 64 | 67 | 3 |
| 33 | 87 | 70 | 58 | 4 ∗ | |||
| FLIPI2 | Clinical | Baseline | NA | NA | 41 | 60 | 3 |
| PRIMA-PI | Clinical | Baseline | 28 | 87 | 52 | 70 | 5 † |
| NA | NA | 35 | 68 | 3 | |||
| m7-FLIPI | Clinical + genetic | Baseline | 48 | 84 | 43 | 86 | 4 ∗ |
| NA | NA | 32 | 79 | 3 | |||
| POD24-PI | Clinical + genetic | Baseline | 40 | 87 | 61 | 73 | 4 ∗ |
| PET/CT TMTV‡ | Imaging | Baseline | 22 | 90 | NA | NA | 6 |
| PET/CT Deauville | Imaging | EOI | 45 | 93 | 56§ | 90§ | 1 |
| ctDNA | Molecular | EOI | 50 | 92 | 40§ | 94§ | 1 |
| PET/CT + ctDNA | Imaging + molecular | EOI | 86 | 94 | 46§ | 99§ | 1 |
Performance parameters of various individual models and integrated scores for the prediction of POD24.
BCCA, British Columbia Cancer Agency; EFS24, event-free survival at 24 months; NA, not applicable; NPV, negative predictive value; PI, prognostic index; TMTV, total metabolic tumor volume.
BCCA validation cohort.
End point: EFS24, derived from supplemental Table 3 of the reference (validation cohort).
TMTV threshold: 510 cm3.
Derived from Tables 2 and 3 of the article by Claudel et al that begins on page 913.